Anonymous
Guest
Anonymous
Guest
Schecter focused on four areas that meet the growth potential needs of "the future Merck".
1) Diabetes
2) Vaccines
3) Acute Care
4) Oncology
He went on to say that these 4 areas currently drive 60% of Mercks' book of business. He stated that the other areas currently generate 40% of our revenue but are projected to be in decline and therefore would not be resourced.
Does this mean PC Respiratory and CV are taking big cuts ?
Does this mean HIV and HCV are perceived to be at peak with no where to go but down ?
Does this mean Osteo has been downgraded ?
Does this mean Neuro/Sleep agent has been downgraded ?
What happens to HQ marketing teams in non-resourced areas ?
Do we lose HSCs across all therapeutic areas, or just those outside the 4 priority areas ?
Losing resource means loss of funding, means loss of head count in those areas.
This is how I interpreted Schecters words.
1) Diabetes
2) Vaccines
3) Acute Care
4) Oncology
He went on to say that these 4 areas currently drive 60% of Mercks' book of business. He stated that the other areas currently generate 40% of our revenue but are projected to be in decline and therefore would not be resourced.
Does this mean PC Respiratory and CV are taking big cuts ?
Does this mean HIV and HCV are perceived to be at peak with no where to go but down ?
Does this mean Osteo has been downgraded ?
Does this mean Neuro/Sleep agent has been downgraded ?
What happens to HQ marketing teams in non-resourced areas ?
Do we lose HSCs across all therapeutic areas, or just those outside the 4 priority areas ?
Losing resource means loss of funding, means loss of head count in those areas.
This is how I interpreted Schecters words.